TABLE 1.
Demographic, Clinical, and Pathologic Characteristics by Group
| Group (#) | All (149) | Anaplasia Positive (64) |
Anaplasia Negative (85) |
P † | Multinucleation Positive (71) |
Multinucleation Negativef (78) |
P † |
|---|---|---|---|---|---|---|---|
| Age (mean ± SD) | 56.6 ± 8.6 | 56.8 ± 9.3 | 56.5 ± 8.0 | 0.85† | 57.2± 9.4 | 57.0 ± 10.4 | 0.43 |
| Sex (%) | 0.56 | 0.90 | |||||
| Male | 137 (91.9) | 60 (93.8) | 85 (91.4) | 65 (91.5) | 72 (92.3) | ||
| Female | 12 (8.1) | 4 (6.2) | 8 (8.6) | 6 (8.5) | 6 (7.7) | ||
| Race (%) | 0.41 | 0.32 | |||||
| White | 134 (90.5) | 56 (87.5) | 78 (92.9) | 62 (87.3) | 72 (93.5) | ||
| Other | 14 (9.5) | 8 (12.5) | 6 (7.1) | 9 (12.7) | 5 (6.5) | ||
| Smoking (%) | 0.056 | 0.35 | |||||
| Yes (current or former) | 95 (66.4) | 45 (76.3) | 50 (59.5) | 47 (71.2) | 48 (62.3) | ||
| No (never) | 48 (33.6) | 14 (23.7) | 34 (40.5) | 19 (28.8) | 29 (37.7) | ||
| T-stage (%) | 0.39 | 0.96 | |||||
| T1/T2 | 100 (67.1) | 40 (62.5) | 60 (70.5) | 47 (66.2) | 53 (67.9) | ||
| T3/T4 | 49 (32.9) | 24 (37.5) | 25 (29.5) | 24 (33.8) | 25 (32.1) | ||
| N-stage (%) | 0.84 | 0.32 | |||||
| N0 | 16 (10.9) | 7 (11.1) | 9 (10.7) | 10 (14.3) | 6 (7.8) | ||
| N1-3 | 131 (89.1) | 56 (88.9) | 75 (89.3) | 60 (85.7) | 71 (92.2) | ||
| Extracapsular extension | 0.10 | 0.004 | |||||
| None | 29 (34.9) | 11 (25.5) | 18 (45.0) | 8 (19.0) | 21 (51.2) | ||
| Present | 54 (65.1) | 32 (74.5) | 22 (55.0) | 34 (81.0) | 20 (48.8) | ||
| Extracapsular extension | 0.66 | 0.13 | |||||
| None or limited | 53 (63.9) | 26 (60.4) | 27 (67.5) | 23 (54.8) | 30 (73.2) | ||
| Extensive (STM) | 30 (36.1) | 17 (39.6) | 13 (32.5) | 19 (45.2) | 11 (26.8) | ||
| Resection margins (%) | 0.44 | 0.20 | |||||
| Negative | 125 (86.8) | 55 (90.2) | 70 (84.3) | 62 (82.7) | 63 (91.3) | ||
| Positive | 19 (13.2) | 6 (9.8) | 13 (15.7) | 13 (17.3) | 6 (8.7) | ||
| IMRT (%) | 0.50 | 0.31 | |||||
| Yes | 139 (93.9) | 59 (92.2) | 80 (95.2) | 65 (91.5) | 74 (96.1) | ||
| No | 9 (6.1) | 5 (78.1) | 4 (4.8) | 6 (8.5) | 3 (3.9) | ||
| Chemotherapy (%) | 0.91 | 0.57 | |||||
| Yes | 58 (45.3) | 32 (56.1) | 38 (53.5) | 36 (58.1) | 34 (51.5) | ||
| No | 70 (54.7) | 25 (43.9) | 33 (46.5) | 26 (41.9) | 32 (48.5) | ||
| Histologic type | < 0.0001 | 0.01 | |||||
| K SCC (type 1) | 22 (14.7) | 15 (23.4) | 7 (8.2) | 16 (22.5) | 6 (7.7) | ||
| NK with maturation (type 2) | 33 (22.1) | 20 (31.2) | 13 (15.3) | 18 (25.6) | 15 (19.2) | ||
| NK SCC (type 3) | 94 (63.1) | 29 (45.3) | 65 (76.5) | 37 (52.1) | 57 (73.1) | ||
| p16 IHC* | 0.10 | 0.03 | |||||
| Positive | 128 (85.9) | 51 (79.7) | 77 (90.6) | 56 (78.9) | 72 (92.3) | ||
| Negative | 21 (14.1) | 13 (20.3) | 8 (9.4) | 15 (21.1) | 6 (7.7) |
Values in bold are statistically significant (P < 0.05)
*
Defined as positive if >50% of tumor cells stained and negative if no staining or < 50% of tumor cells stained.
†
P-values indicate correlation between demographic, clinical, or pathologic variables with anaplasia and multinucleation. The P-values are derived from a 2-sample t test for age and Χ2 or Fisher exact tests as appropriate for others.
IHC indicates immunohistochemistry; IMRT, intensity-modulated radiation therapy; K SCC, keratinizing-type SCC; STM, soft tissue metastasis.